These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878 [TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J Front Immunol; 2022; 13():1006860. PubMed ID: 36189211 [TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
10. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors. Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879 [TBL] [Abstract][Full Text] [Related]
11. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171 [TBL] [Abstract][Full Text] [Related]
12. T cell checkpoint regulators in the heart. Grabie N; Lichtman AH; Padera R Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928 [TBL] [Abstract][Full Text] [Related]
14. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918 [TBL] [Abstract][Full Text] [Related]
15. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives]. Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886 [TBL] [Abstract][Full Text] [Related]
16. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Sibaud V Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113 [TBL] [Abstract][Full Text] [Related]
17. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Yao J; Li M; Zhang H; Ge Y; Weygant N; An G Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598 [TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597 [TBL] [Abstract][Full Text] [Related]